Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus

NCT01220856 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT01220856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01220856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2010
Completion date
April 30, 2013
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic islet transplantation in type 1 diabetes mellitus